Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

Active, not recruiting

Conditions: Cystic Fibrosis

First Posted Date: 2024-07-17

Last Posted Date: 2025-06-06

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 79

Registration Number: NCT06506773

Locations: 🇺🇸
Johns Hopkins All Children's Hospital Outpatient Care Center, Saint Petersburg, Florida, United States
🇺🇸
St. Luke's Cystic Fibrosis Center of Idaho, Boise, Idaho, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 47 locations

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Phase 3

Conditions: Cystic Fibrosis

Interventions: Drug: ELX/TEZ/IVA
Drug: IVA

First Posted Date: 2024-06-14

Last Posted Date: 2025-06-19

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 50

Registration Number: NCT06460506

Locations: 🇦🇺
The Kids Research Institute Australia, Nedlands, Australia
🇦🇺
The Royal Children's Hospital, Parkville, Australia
🇦🇺
Queensland Children's Hospital, South Brisbane, Australia

and more 15 locations

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-150
Drug: Placebo
Drug: VX-993
Drug: VX-548

First Posted Date: 2024-05-20

Last Posted Date: 2025-04-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 92

Registration Number: NCT06420765

Locations: 🇬🇧
MAC Clinical Research, Manchester, United Kingdom

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: VX-993

First Posted Date: 2024-05-01

Last Posted Date: 2025-03-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 88

Registration Number: NCT06394167

Locations: 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States

A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-993
Drug: Midazolam
Drug: Itraconazole
Drug: Gemfibrozil

First Posted Date: 2024-04-30

Last Posted Date: 2024-08-01

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 42

Registration Number: NCT06392659

Locations: 🇬🇧
MAC Clinical Research, Manchester, United Kingdom

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions: Drug: VX-407
Drug: Placebo
Drug: Midazolam

First Posted Date: 2024-04-03

Last Posted Date: 2025-05-31

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 159

Registration Number: NCT06345755

Locations: 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
🇨🇦
Altasciences Montreal, Montreal, Canada

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Suzetrigine

First Posted Date: 2024-03-28

Last Posted Date: 2024-07-19

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 48

Registration Number: NCT06336096

Locations: 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-118

First Posted Date: 2024-03-15

Last Posted Date: 2024-06-03

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 15

Registration Number: NCT06312787

Locations: 🇺🇸
Celerion - Lincoln, Lincoln, Nebraska, United States

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VNZ/TEZ/D-IVA

First Posted Date: 2024-03-08

Last Posted Date: 2024-05-16

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 10

Registration Number: NCT06299696

Locations: 🇺🇸
Site 001, Woburn, Massachusetts, United States

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VNZ/TEZ/D-IVA

First Posted Date: 2024-03-08

Last Posted Date: 2024-06-24

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 34

Registration Number: NCT06299709

Locations: 🇺🇸
Celerion, Inc., Tempe, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy